LBIO (Longevity Biomedical) FCF Margin %: 0.00% (As of . 20)


What is Longevity Biomedical FCF Margin %?

Longevity Biomedical LBIO FCF Margin % is 0.00% as of . 20.

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Longevity Biomedical's Free Cash Flow for the six months ended in . 20 was $0.00 Mil. Longevity Biomedical's Revenue for the six months ended in . 20 was $0.00 Mil. Therefore, Longevity Biomedical's FCF Margin % for the quarter that ended in . 20 was 0.00%.

As of today, Longevity Biomedical's current FCF Yield % is 0.00%.

The historical rank and industry rank for Longevity Biomedical's FCF Margin % or its related term are showing as below:


LBIO's FCF Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -84.65
* Ranked among companies with meaningful FCF Margin % only.

Longevity Biomedical FCF Margin % Related Terms

Longevity Biomedical FCF Margin % Historical Data

* Premium members only.

The historical data trend for Longevity Biomedical's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Longevity Biomedical FCF Margin % Chart

Longevity Biomedical Annual Data
Trend
FCF Margin %

Longevity Biomedical Semi-Annual Data
FCF Margin %

LBIO vs : FCF Margin % Comparison

For the Biotechnology subindustry, Longevity Biomedical's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Longevity Biomedical FCF Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Longevity Biomedical's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Longevity Biomedical's FCF Margin % falls into.


Longevity Biomedical FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Longevity Biomedical's FCF Margin for the fiscal year that ended in . 20 is calculated as

FCF Margin=Free Cash Flow (A: . 20 )/Revenue (A: . 20 )
=/
= %

Longevity Biomedical's FCF Margin for the quarter that ended in . 20 is calculated as

FCF Margin=Free Cash Flow (Q: . 20 )/Revenue (Q: . 20 )
=/
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about FCF Margin % →
What does a FCF Margin % of 0.00% mean?
Longevity Biomedical (LBIO) has a FCF Margin % of 0.00% as of . 20. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Longevity Biomedical and its competitors.
Is Longevity Biomedical's FCF Margin % too high?
Longevity Biomedical's current FCF Margin % is 0.00%.
How does Longevity Biomedical's FCF Margin % compare to ?
Longevity Biomedical's FCF Margin % of 0.00% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Biotechnology company?
A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Longevity Biomedical and its competitors. Longevity Biomedical's current FCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Longevity Biomedical stock overvalued right now?
Longevity Biomedical (LBIO) has a current FCF Margin % of 0.00%. The current FCF Margin % is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Longevity Biomedical (LBIO), the current FCF Margin % is 0.00% as of . 20. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Longevity Biomedical Business Description

Comparable Companies
Address 12100 NE 195th street, Suite 150, Bothell, WA, USA, 98011
Longevity Biomedical Inc is a clinical-stage biomedical company. The company is focused on the advancement of new technologies across therapeutics, monitoring, and digital health that aim to restore tissue form and function to increase health span. Longevity is acquiring a differentiated therapeutic pipeline of late-stage clinical technologies across ophthalmology, cardiovascular disease, and soft tissue reconstruction and repair.